Should I buy or sell Hookipa Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares. View HOOK analyst ratings or view top-rated stocks .

What is Hookipa Pharma's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price targets for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price. View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts .

How have HOOK shares performed in 2023?

Hookipa Pharma's stock was trading at $0.81 on January 1st, 2023. Since then, HOOK shares have decreased by 29.0% and is now trading at $0.5750. View the best growth stocks for 2023 here .

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our HOOK earnings forecast .

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm earned $6.87 million during the quarter, compared to the consensus estimate of $3.39 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 336.12%.

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX) , Kaleido Biosciences (KLDO) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Atreca (BCEL) , LogicBio Therapeutics (LOGC) , Alector (ALEC) , Precision BioSciences (DTIL) , Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX) .

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.42%), FMR LLC (4.00%), Redmile Group LLC (1.27%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Igor Matushansky, Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr. View institutional ownership trends .

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Hookipa Pharma Stock Price, News & Analysis (NASDAQ:HOOK)

$0.57

+0.01 (+1.77%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.55
▼
$0.60
50-Day Range: $0.42
▼
$0.63
52-Week Range: $0.41
▼
$2.05

Volume: 327,804 shs
Average Volume: 651,893 shs
Market Capitalization: $48.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.83

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 914.5% Upside
$5.83 Price Target
Short Interest: Healthy
0.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.02) to ($0.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

180th out of 951 stocks

Pharmaceutical Preparations Industry

71st out of 436 stocks

3.5

Analyst's Opinion

Consensus Rating
Hookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.83, Hookipa Pharma has a forecasted upside of 914.5% from its current price of $0.58.
Amount of Analyst Coverage
Hookipa Pharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.31% of the float of Hookipa Pharma has been sold short.
Short Interest Ratio / Days to Cover
Hookipa Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hookipa Pharma has recently decreased by 26.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Hookipa Pharma does not currently pay a dividend.
Dividend Growth
Hookipa Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOOK.

3.3

News and Social Media Coverage

News Sentiment
Hookipa Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Hookipa Pharma this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for HOOK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
2 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hookipa Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.82% of the stock of Hookipa Pharma is held by insiders.
Percentage Held by Institutions
83.02% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Hookipa Pharma are expected to grow in the coming year, from ($1.02) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hookipa Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hookipa Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hookipa Pharma has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOOK Stock News Headlines

November 20, 2023 | markets.businessinsider.com

HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV

November 20, 2023 | finance.yahoo.com

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 12, 2023 | markets.businessinsider.com

Promising Clinical Trials and Strong Financial Performance Bolster Buy Rating for Hookipa Pharma

November 10, 2023 | markets.businessinsider.com

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 9, 2023 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 9, 2023 | msn.com

HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M

November 9, 2023 | finance.yahoo.com

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 9, 2023 | finance.yahoo.com

HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023

November 3, 2023 | finance.yahoo.com

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

November 2, 2023 | finance.yahoo.com

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

October 22, 2023 | finance.yahoo.com

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

October 18, 2023 | finance.yahoo.com

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

September 27, 2023 | markets.businessinsider.com

Analyst Ratings for HOOKIPA Pharma

September 27, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Buy Rating on Hookipa Pharma (HOOK)

September 13, 2023 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Announces Executive Leadership Change

September 13, 2023 | finance.yahoo.com

HOOKIPA Announces Executive Leadership Change

September 12, 2023 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2023 | finance.yahoo.com

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2023 | finance.yahoo.com

Some Analysts Just Cut Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates

August 12, 2023 | markets.businessinsider.com

RBC Capital Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)

August 11, 2023 | msn.com

HC Wainwright & Co. Maintains Hookipa Pharma (HOOK) Buy Recommendation

August 10, 2023 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 10, 2023 | finance.yahoo.com

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2023 | finance.yahoo.com

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 3, 2023 | finance.yahoo.com

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

See More Headlines

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HOOK
CUSIP: N/A
CIK: 1760542
Web: www.hookipapharma.com
Phone: 431-890-6360
Fax: 43-1890-636-0399
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.83
High Stock Price Target: $7.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +914.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,920,000.00
Net Margins: -336.12%
Pretax Margin: -334.01%
Return on Equity: -70.24%
Return on Assets: -40.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.44
Quick Ratio: 3.44

Sales & Book Value

Annual Sales: $14.25 million
Price / Sales: 3.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.13 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 83,950,000
Free Float: 79,064,000
Market Cap: $48.27 million
Optionable: Not Optionable
Beta: 0.89

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Joern Aldag (Age 60)
Pres, CEO & Director
Mr. Daniel Pinschewer (Age 44)
Founder & Chief Scientific Officer
Dr. Reinhard Kandera (Age 50)
CFO & Director
Mr. Anders Lilja Ph.D. (Age 46)
Sr. VP of Technical Devel.
Mrs. Nina Waibel
Communications & Investor Relations Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings or view top-rated stocks.
What is Hookipa Pharma's stock price target for 2024?: 3 Wall Street research analysts have issued twelve-month price targets for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price.
View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts.
How have HOOK shares performed in 2023?: Hookipa Pharma's stock was trading at $0.81 on January 1st, 2023. Since then, HOOK shares have decreased by 29.0% and is now trading at $0.5750.
View the best growth stocks for 2023 here.
When is Hookipa Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our HOOK earnings forecast.
How were Hookipa Pharma's earnings last quarter?: Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm earned $6.87 million during the quarter, compared to the consensus estimate of $3.39 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 336.12%.

What other stocks do shareholders of Hookipa Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).
When did Hookipa Pharma IPO?: (HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.
Who are Hookipa Pharma's major shareholders?: Hookipa Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.42%), FMR LLC (4.00%), Redmile Group LLC (1.27%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Igor Matushansky, Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr.
View institutional ownership trends.
How do I buy shares of Hookipa Pharma?: Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial